Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rV-NY-ESO-1 and rF-NY-ESO-1 in Ovarian Cancer
NCT00112957Phase 2Completed
- Sponsor
- Ludwig Cancer Research
- Start
- Dec 2004
- Primary completion
- May 2009
- Modality
- Viral Vector Vaccines, Oncolytic Viruses
- Countries
- 1
01
Overview
A Phase 2 trial of rV-NY-ESO-1, recombinant fowlpox-NY-ESO-1 in ovarian epithelial cancer, fallopian tube cancer (PFTC), primary peritoneal carcinoma (PPC), sponsored by Ludwig Cancer Research. Started Dec 2004; status: completed.
02
Drugs
rV-NY-ESO-1recombinant fowlpox-NY-ESO-1
03
Conditions
ovarian epithelial cancerfallopian tube cancer (PFTC)primary peritoneal carcinoma (PPC)
Beyond the preview
Go deeper on NCT00112957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00112957.